Display options
Cite
Shah UA, Rögnvaldsson S, Derkach A, et al. Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica. 2022;107(1):284-286doi: 10.3324/haematol.2021.278772.
Shah, U. A., Rögnvaldsson, S., Derkach, A., Björkholm, M., Turesson, I., David, Y., Hultcrantz, M., Tan, C., Hassoun, H., Korde, N., Lesokhin, A., Mailankody, S., Kristinsson, S. Y., & Landgren, C. O. (2022). Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica, 107(1), 284-286. https://doi.org/10.3324/haematol.2021.278772
Shah, Urvi A, et al. "Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls." Haematologica vol. 107,1 (2022): 284-286. doi: https://doi.org/10.3324/haematol.2021.278772
Shah UA, Rögnvaldsson S, Derkach A, Björkholm M, Turesson I, David Y, Hultcrantz M, Tan C, Hassoun H, Korde N, Lesokhin A, Mailankody S, Kristinsson SY, Landgren CO. Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica. 2022 Jan 01;107(1):284-286. doi: 10.3324/haematol.2021.278772. PMID: 34474548; PMCID: PMC8719074.
Copy Download .nbib Format: NLM
Share it on

Haematologica. 2022 Jan 01;107(1):284-286. doi: 10.3324/haematol.2021.278772.

Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls.

Haematologica

Urvi A Shah, Sæmundur Rögnvaldsson, Andriy Derkach, Magnus Björkholm, Ingemar Turesson, Yael David, Malin Hultcrantz, Carlyn Tan, Hani Hassoun, Neha Korde, Alexander Lesokhin, Sham Mailankody, Sigurður Yngvi Kristinsson, C Ola Landgren

Affiliations

  1. Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York. [email protected].
  2. Department of Medicine, University of Iceland.
  3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York.
  4. Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm.
  5. Department of Hematology, Skane University Hospital Malmö/Lund.
  6. Department of Chemical Biology, Sloan Kettering Institute, New York.
  7. Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York.
  8. Department of Medicine, University of Iceland, Iceland; Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm.
  9. Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami.

PMID: 34474548 PMCID: PMC8719074 DOI: 10.3324/haematol.2021.278772

[No abstract available.]

References

  1. Nephron Extra. 2014 Jul 22;4(2):119-26 - PubMed
  2. Diabetologia. 2014 Nov;57(11):2261-9 - PubMed
  3. Acta Diabetol. 2021 Feb;58(2):153-168 - PubMed
  4. Diabetologia. 2021 Mar;64(3):540-551 - PubMed
  5. Blood. 2012 May 24;119(21):4845-50 - PubMed
  6. Nat Rev Nephrol. 2019 Jun;15(6):346-366 - PubMed
  7. Blood. 2008 Oct 15;112(8):3052-6 - PubMed
  8. Haematologica. 2008 Jun;93(6):842-50 - PubMed
  9. Lancet Haematol. 2015 Jan;2(1):e30-6 - PubMed
  10. Lancet Diabetes Endocrinol. 2021 Mar;9(3):165-173 - PubMed
  11. Am J Epidemiol. 2016 Jun 15;183(12):1098-106 - PubMed
  12. J Clin Endocrinol Metab. 2020 Aug 1;105(8): - PubMed
  13. Amyloid. 2000 Dec;7(4):227-44 - PubMed
  14. Eur J Cancer. 2005 Aug;41(12):1782-7 - PubMed
  15. Diabetes Care. 2008 Dec;31(12):2391-7 - PubMed

Publication Types

Grant support